Compare JBI & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JBI | ATXS |
|---|---|---|
| Founded | 2002 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 821.8M | 722.1M |
| IPO Year | N/A | 2015 |
| Metric | JBI | ATXS |
|---|---|---|
| Price | $6.43 | $12.96 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 4 | 6 |
| Target Price | $10.13 | ★ $24.33 |
| AVG Volume (30 Days) | ★ 1.9M | 992.4K |
| Earning Date | 11-06-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.34 | N/A |
| Revenue | ★ $888,700,000.00 | $706,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.58 | N/A |
| P/E Ratio | $18.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.73 | $3.56 |
| 52 Week High | $10.80 | $12.72 |
| Indicator | JBI | ATXS |
|---|---|---|
| Relative Strength Index (RSI) | 35.76 | 71.88 |
| Support Level | $5.97 | $12.55 |
| Resistance Level | $6.28 | $12.69 |
| Average True Range (ATR) | 0.24 | 0.20 |
| MACD | 0.14 | -0.08 |
| Stochastic Oscillator | 97.14 | 99.26 |
Janus International Group Inc is a manufacturer and supplier of turnkey solutions for self-storage, commercial, and industrial building Solutions. The company provides products that include roll-up and swing doors, hallway systems, relocatable storage MASS (Moveable Additional Storage Structures) units, and technologies for automating facility and door operation. It is operated through two geographic regions; Janus North America and Janus International. The Janus International segment is comprised of a subsidiary whose production and sales are largely in Europe and Australia. The Janus North America segment is comprised of all the other entities.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.